BRANFORD, Conn. / Jul 30, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston August 13-15, 2024.
Jeff Hawkins, Quantum-Si's Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13th, at 11:00 AM ET.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.32 |
| Daily Change: | 0.01 0.76 |
| Daily Volume: | 5,279,765 |
| Market Cap: | US$205.870M |
December 20, 2024 December 04, 2024 November 21, 2024 November 20, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
